- Report
- September 2023
- 149 Pages
Global
From €2401EUR$2,499USD£2,053GBP
- Report
- February 2024
- 110 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- September 2023
- 190 Pages
Global
From €2392EUR$2,490USD£2,045GBP
- Report
- April 2024
- 185 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- November 2023
- 178 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- June 2023
- 119 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- March 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- January 2024
- 200 Pages
Global
From €3987EUR$4,150USD£3,409GBP
- Report
- October 2023
- 172 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- December 2023
- 140 Pages
Global
From €4276EUR$4,450USD£3,656GBP
- Report
- March 2024
- 200 Pages
Global
From €3987EUR$4,150USD£3,409GBP
- Report
- January 2024
- 200 Pages
Global
From €3987EUR$4,150USD£3,409GBP
- Report
- January 2024
- 168 Pages
Global
€4799EUR$4,995USD£4,103GBP
- Report
- January 2024
- 94 Pages
United States
From €5717EUR$5,950USD£4,888GBP
- Report
- August 2022
- 214 Pages
Global
From €4611EUR$4,799USD£3,942GBP
- Report
- September 2022
- 377 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- August 2022
- 240 Pages
Global
From €4611EUR$4,799USD£3,942GBP
- Report
- November 2022
- 286 Pages
Global
From €5044EUR$5,250USD£4,313GBP
- Report
- June 2022
- 257 Pages
Global
From €5044EUR$5,250USD£4,313GBP
Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more